Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Anti-platelet Therapy in COPD
NCT05567562Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aspirin and clopidogrel in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Pulmonary Microvascular Blood Volume, Coefficient of Variation at 2 weeks. Started Mar 2024; status: completed.
02
Drugs
aspirinclopidogrel
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05567562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567562.